Department of General Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ, USA.
Shock. 2013 Jan;39(1):39-44. doi: 10.1097/SHK.0b013e31827b450d.
We tested if vagus nerve stimulation (VNS) would prevent gut injury, mesenteric lymph toxicity, and systemic multiple organ dysfunction syndrome following trauma-hemorrhagic shock (T/HS). Four groups of experiments were performed. The first tested whether VNS (5 V for 10 min) would protect against T/HS-induced increases in gut and lung permeability as well as neutrophil priming. In the second experiment, mesenteric lymph was collected from rats subjected to T/HS or trauma-sham shock with or without VNS and then injected into naive mice to assess its biologic activity. Lung permeability, neutrophil priming, and red blood cell deformability were measured. Next, the role of the spleen in VNS-mediated protection was tested by measuring gut and lung injury in splenectomized rats subjected to sham or actual VNS. Lastly, the ability of nicotine to replicate the gut-protective effect of VNS was tested. Vagus nerve stimulation protected against T/HS-induced gut injury, lung injury, and neutrophil priming (P < 0.05). Not only did VNS limit organ injury after T/HS, but in contrast to the mesenteric lymph collected from the sham-VNS T/HS rats, the mesenteric lymph from the VNS T/HS rats did not cause lung injury, neutrophil priming, or loss of red blood cell deformability (P < 0.05) when injected into naive mice. Removal of the spleen did not prevent the protective effects of VNS on gut or lung injury after T/HS. Similar to VNS, the administration of nicotine also protected the gut from injury after T/HS. Vagus nerve stimulation prevents T/HS-induced gut injury, lung injury, neutrophil priming, and the production of biologically active mesenteric lymph. This protective effect of VNS was not dependent on the spleen but appeared to involve a cholinergic nicotinic receptor, because its beneficial effects could be replicated with nicotine.
我们测试了迷走神经刺激(VNS)是否可以预防创伤性失血性休克(T/HS)后的肠道损伤、肠系膜淋巴毒性和全身多器官功能障碍综合征。进行了四组实验。第一项测试是 VNS(5V 持续 10 分钟)是否可以防止 T/HS 引起的肠道和肺部通透性增加以及中性粒细胞的激活。在第二项实验中,从接受 T/HS 或创伤性假休克的大鼠中收集肠系膜淋巴,如果有 VNS 则进行收集,如果没有 VNS 则不进行收集,然后将其注入到未接受处理的小鼠中,以评估其生物学活性。测量了肺通透性、中性粒细胞激活和红细胞变形性。接下来,通过测量接受假 VNS 或实际 VNS 的脾切除术大鼠的肠道和肺部损伤,测试了脾脏在 VNS 介导的保护中的作用。最后,测试了尼古丁复制 VNS 对肠道保护作用的能力。VNS 可预防 T/HS 引起的肠道损伤、肺损伤和中性粒细胞激活(P<0.05)。VNS 不仅限制了 T/HS 后的器官损伤,而且与来自 sham-VNS T/HS 大鼠的肠系膜淋巴相比,来自 VNS T/HS 大鼠的肠系膜淋巴在注入未接受处理的小鼠后不会引起肺损伤、中性粒细胞激活或红细胞变形性丧失(P<0.05)。脾切除术并不能阻止 VNS 对 T/HS 后肠道或肺部损伤的保护作用。与 VNS 相似,尼古丁的给药也可以保护肠道免受 T/HS 后的损伤。VNS 可预防 T/HS 引起的肠道损伤、肺损伤、中性粒细胞激活和生物活性肠系膜淋巴的产生。VNS 的这种保护作用不依赖于脾脏,但似乎涉及胆碱能烟碱受体,因为其有益作用可以用尼古丁复制。